Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-1.56 Insider Own0.40% Shs Outstand46.24M Perf Week-10.35%
Market Cap2.19B Forward P/E- EPS next Y-3.30 Insider Trans-86.17% Shs Float36.85M Perf Month-10.74%
Income-62.10M PEG- EPS next Q-0.67 Inst Own43.50% Short Float6.56% Perf Quarter21.89%
Sales41.00M P/S53.31 EPS this Y18.10% Inst Trans1.80% Short Ratio2.03 Perf Half Y147.88%
Book/sh4.64 P/B10.19 EPS next Y-14.80% ROA-23.20% Target Price63.38 Perf Year185.10%
Cash/sh5.19 P/C9.11 EPS next 5Y- ROE-35.10% 52W Range13.50 - 61.24 Perf YTD101.32%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-22.81% Beta-
Dividend %- Quick Ratio17.10 Sales past 5Y- Gross Margin- 52W Low250.15% ATR4.53
Employees127 Current Ratio17.10 Sales Q/Q1279.10% Oper. Margin- RSI (14)46.78 Volatility9.58% 9.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-88.60% Profit Margin- Rel Volume1.09 Prev Close49.60
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.19M Price47.27
Recom2.10 SMA20-2.53% SMA50-1.85% SMA20069.07% Volume1,289,442 Change-4.70%
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Apr-23-18 10:00AM  Geron Corporation: The Clock Is Ticking Motley Fool -8.27%
06:34AM  What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years? Simply Wall St.
Apr-20-18 05:12PM  Big Week in Tech for Amazon, Alphabet and Microsoft Yahoo Finance Video -5.83%
Apr-16-18 04:01PM  CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 GlobeNewswire
Apr-13-18 08:00AM  CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 GlobeNewswire
Apr-12-18 08:25AM  Market Trends Toward New Normal in Argo Group International, Methanex, Industrias Bachoco, S.A. de C.V, CRISPR Therapeutics AG, Astec Industries, and Sprague Resources LP Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +5.52%
Apr-04-18 04:01PM  CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs GlobeNewswire
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
Mar-26-18 04:01PM  CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property GlobeNewswire
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Mar-15-18 05:09PM  Why CRISPR Therapeutics Slipped 10% on Thursday Motley Fool -9.58%
08:10AM  Todays Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax Pharmaceuticals ACCESSWIRE
07:10AM  Here are some biotech song requests for Diana Ross at the 2018 BIO convention American City Business Journals
Mar-14-18 07:40AM  Analysis: Positioning to Benefit within CURO Group, Golar LNG Partners LP, CRISPR Therapeutics AG, Kinross Gold, Enerplus, and ManTech International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-13-18 07:30AM  Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS) ACCESSWIRE
Mar-09-18 03:36PM  Here's Why CRISPR Therapeutics AG Gained as Much as 14% Today Motley Fool +5.62%
Mar-08-18 04:15PM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-04-18 11:36AM  Here's Why Crispr Therapeutics AG Jumped Again in February Motley Fool
Mar-03-18 07:07AM  3 Stocks That Look Just Like eBay in 1998 Motley Fool
Mar-02-18 09:21PM  Heres Why Gilead Sciences' Jump Into Gene Editing Is Important Motley Fool +7.48%
03:29PM  CRISPR Takes a Leap Forward With Huntington's Disease GuruFocus.com
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and CRISPR Therapeutics ACCESSWIRE
Feb-21-18 08:30AM  CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire
Feb-15-18 06:02AM  3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate Motley Fool
Feb-08-18 04:30PM  CRISPR Therapeutics Announces Transition of Bill Lundberg, MD GlobeNewswire -7.27%
01:35PM  Why Crispr Therapeutics AG Stock Bolted Higher in January Motley Fool
12:55PM  Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in January Motley Fool
Feb-07-18 10:53AM  The Confidence in the Dip Buyers Has Weakened TheStreet.com +13.98%
Feb-05-18 07:10PM  Cramer's lightning round: Tableau Software is exactly the... CNBC Videos
Feb-02-18 03:10PM  Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases? Investor's Business Daily
Jan-31-18 01:29PM  [$$] Bayer Buys More Crispr Stock After Celgene Sells Barrons.com -5.80%
Jan-30-18 12:03PM  Here's Why Editas Medicine Rose as Much as 15.7% Yesterday Motley Fool -6.06%
Jan-28-18 03:28PM  3 Biotech Stocks With Jaw-Dropping Growth Potential Motley Fool
Jan-24-18 08:00AM  Celgene's Been Selling Shares in This Biotech Motley Fool
Jan-23-18 03:50PM  2 Gene Editing Stocks SunTrust Recommends Benzinga +14.90%
12:57PM  Here's What's Driving Crispr Therapeutics AG Higher Today Motley Fool
05:20AM  Chinese scientists used Crispr gene editing on 86 human patients Quartz
Jan-22-18 12:45AM  [$$] China, Unhampered by Rules, Races Ahead in Gene-Editing Trials The Wall Street Journal +13.52%
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool
Jan-09-18 06:09AM  10 Things to Expect From Vertex Pharmaceuticals in 2018 Motley Fool
Jan-08-18 08:46AM  CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% Zacks
08:00AM  Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless Motley Fool
03:00AM  Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating Investor's Business Daily
Jan-05-18 01:48PM  Why CRISPR Therapeutics AG Stock Is Rising Today Motley Fool +12.13%
12:10PM  Investors Cheer Secondary Offering for Gene-Editing Firm 24/7 Wall St.
Jan-04-18 07:03PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire
04:36PM  Here's Why Intellia Therapeutics Inc. Fell 14.7% in December Motley Fool
10:47AM  Here's What Pushed Crispr Therapeutics AG Up 23.6% in December Motley Fool
Jan-03-18 06:15AM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire -6.56%
Dec-27-17 01:24PM  [$$] Celgene: Two Small-Cap Biotech Stocks It's Selling Barrons.com
08:55AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-22-17 12:32PM  CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know Motley Fool +8.02%
Dec-21-17 08:00AM  CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board GlobeNewswire
Dec-12-17 08:30AM  Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia Business Wire
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
07:45AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
Dec-07-17 07:00AM  CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia GlobeNewswire
Dec-05-17 08:00AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
07:47AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : December 5, 2017 Capital Cube
Nov-29-17 08:26PM  Bitcoin or CRISPR: Which is the Bigger Disruptor? Zacks
Nov-28-17 08:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals
Nov-21-17 07:33AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 21, 2017 Capital Cube
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
Nov-13-17 11:20AM  MIT scientists deploy new CRISPR delivery system to edit genes in mice American City Business Journals
08:00AM  CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer GlobeNewswire
05:00AM  CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs GlobeNewswire
Nov-10-17 08:00PM  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting GlobeNewswire
Nov-08-17 04:05PM  CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-07-17 03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
11:40AM  Why CRISPR Therapeutics AG Stock Edged Higher in October Motley Fool
08:00AM  CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting GlobeNewswire
07:04AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 7, 2017 Capital Cube
Oct-30-17 12:38PM  CRISPR Therapeutics AG Value Analysis (NASDAQ:CRSP) : October 30, 2017 Capital Cube
Oct-27-17 08:29AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 27, 2017 Capital Cube
Oct-13-17 08:30AM  CRISPR Therapeutics Awarded Grant from Friedreichs Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrichs Ataxia GlobeNewswire
Oct-12-17 08:24AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 12, 2017 Capital Cube
Oct-10-17 10:00AM  Why CRISPR Therapeutics AG Stock Lost Ground in September Motley Fool
Oct-04-17 04:01PM  CRISPR Therapeutics to Present at Investor Conferences in October GlobeNewswire
Oct-02-17 07:30AM  CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer GlobeNewswire
Sep-27-17 08:17AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : September 27, 2017 Capital Cube
Sep-18-17 12:38PM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-07-17 03:32PM  Breaking Down Barclays' New Bullish Calls On Biotech Benzinga
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-24-17 10:50AM  CRISPR Therapeutics, MGH team up on new cancer treatments American City Business Journals +5.11%
Aug-22-17 07:30AM  CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies GlobeNewswire
Aug-13-17 11:01AM  This Technology Could Make You Rich -- and Change the World As We Know It Motley Fool
Aug-10-17 04:35PM  CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-01-17 07:00AM  CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development GlobeNewswire
Jul-25-17 05:00PM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing GlobeNewswire
Jul-17-17 07:06AM  This Is Why Investors Will Need to Learn a New Acronym: CRISPR Motley Fool
Jul-15-17 03:40PM  Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool
12:03PM  Why You're Smart to Buy Vertex Pharmaceuticals Stock Motley Fool
Jul-10-17 12:35PM  Why CRISPR Therapeutics AG Jumped 11.7% in June Motley Fool
08:30AM  CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration GlobeNewswire
08:00AM  CRISPR Gene Editing Controversy: Does It Really Cause Unexpected Mutations? Forbes
Jul-09-17 06:02AM  3 Growth Stocks for Forward-Looking Investors Motley Fool
Jul-05-17 04:30PM  CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium GlobeNewswire
Jun-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : June 23, 2017 Capital Cube
Jun-19-17 07:30AM  CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China GlobeNewswire
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
Versant Venture Capital IV, L.10% OwnerApr 23Sale50.68101,9945,168,90145,171Apr 24 07:44 PM
Woiwode ThomasDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:42 PM
Bolzon Bradley J PhDDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:41 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Option Exercise12.5721,000263,97045,094Jan 18 05:38 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Sale28.0366,0001,850,25525,204Jan 18 05:38 PM
EMSTER KURT VONDirectorJan 05Buy22.7565,9341,499,9991,887,202Jan 11 09:00 PM
BAYER AKTIENGESELLSCHAFT10% OwnerJan 05Buy22.75527,47211,999,9885,632,802Jan 30 02:21 PM
EMSTER KURT VONDirectorJan 05Sale26.9692,3372,489,4061,821,268Jan 09 04:39 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Option Exercise12.578,000100,56078,204Jan 04 07:14 PM
EMSTER KURT VONDirectorJan 02Sale26.7637,7541,010,1231,913,605Jan 04 05:29 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Sale21.6438,000822,50070,204Jan 04 07:14 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Option Exercise13.3315,300203,909124,274Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Sale22.7430,300689,055100,204Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Option Exercise14.4370010,101115,904Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Sale21.7570015,225115,204Jan 02 04:18 PM
Bolzon Bradley J PhDDirectorDec 22Sale20.3026,016528,23727,724Dec 27 04:17 PM
Dylan-Hyde TylerChief Legal OfficerDec 22Sale20.5515,000308,250115,204Dec 27 04:17 PM
Woiwode ThomasDirectorDec 22Sale20.293,05962,0704,959Dec 27 04:14 PM
Kulkarni SamarthChief Executive OfficerDec 21Option Exercise1.8115,00027,150148,560Dec 26 05:11 PM
Dylan-Hyde TylerChief Legal OfficerDec 15Sale18.9015,000283,496130,204Dec 19 04:10 PM
CELGENE CORP /DE/10% OwnerDec 04Sale19.4730,485593,5433,722,534Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 01Sale19.1087,9911,680,6283,753,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 30Sale19.0412,666241,1613,841,010Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 29Sale19.254,26382,0633,853,676Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 28Sale19.225,08097,6383,857,939Dec 07 09:57 AM
Woiwode ThomasDirectorNov 27Sale20.242004,0488,018Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 27Sale20.242004,04853,740Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 27Sale19.7527,990552,8033,863,019Dec 07 09:57 AM
Woiwode ThomasDirectorNov 24Sale20.211,70034,3588,218Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 24Sale20.211,50730,45053,940Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 24Sale20.0026,010520,2003,891,009Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 22Sale19.76256,0005,058,5603,917,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 20Sale19.02158,7183,018,8164,253,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 17Sale18.4451,282945,6404,411,737Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 16Sale18.39105,0001,930,9504,463,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 15Sale17.6715,000265,0504,568,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 14Sale17.1914,907256,2514,583,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 13Sale17.7665,0931,156,0524,597,926Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 10Sale17.2810,000172,8004,663,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 09Sale17.0820,000341,6004,673,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 08Sale18.0616,875304,7634,693,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 07Sale18.5423,000426,4204,709,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 06Sale18.8979,3271,498,4874,732,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 03Sale19.1022,759434,6974,812,221Dec 07 09:57 AM
Novak RodgerChief Executive OfficerSep 05Option Exercise1.813,8536,9741,151,860Sep 05 06:33 PM
Novak RodgerChief Executive OfficerSep 05Sale20.333,85378,3201,148,007Sep 05 06:33 PM
Novak RodgerChief Executive OfficerAug 31Sale20.8714,617305,0731,148,007Sep 05 06:33 PM